000 | 01996 a2200517 4500 | ||
---|---|---|---|
005 | 20250517100217.0 | ||
264 | 0 | _c20171002 | |
008 | 201710s 0 0 eng d | ||
022 | _a1567-7257 | ||
024 | 7 |
_a10.1016/j.meegid.2016.05.035 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aAmponsah-Dacosta, Edina | |
245 | 0 | 0 |
_aEvidence of susceptibility to lamivudine-based HAART and genetic stability of hepatitis B virus (HBV) in HIV co-infected patients: A South African longitudinal HBV whole genome study. _h[electronic resource] |
260 |
_bInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases _c09 2016 |
||
300 |
_a232-8 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAnti-HIV Agents _xtherapeutic use |
650 | 0 | 4 | _aAntiretroviral Therapy, Highly Active |
650 | 0 | 4 | _aCoinfection |
650 | 0 | 4 |
_aDNA, Viral _xgenetics |
650 | 0 | 4 | _aEvolution, Molecular |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aGenome, Viral |
650 | 0 | 4 | _aGenotype |
650 | 0 | 4 |
_aHIV _xdrug effects |
650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
650 | 0 | 4 |
_aHepatitis B virus _xdrug effects |
650 | 0 | 4 |
_aHepatitis B, Chronic _xdrug therapy |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aLamivudine _xtherapeutic use |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMicrobial Sensitivity Tests |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aRetrospective Studies |
650 | 0 | 4 | _aSouth Africa |
650 | 0 | 4 | _aViral Load |
700 | 1 | _aRakgole, J Nare | |
700 | 1 | _aGededzha, Maemu P | |
700 | 1 | _aLukhwareni, Azwidowi | |
700 | 1 | _aBlackard, Jason T | |
700 | 1 | _aSelabe, Selokela G | |
700 | 1 | _aMphahlele, M Jeffrey | |
773 | 0 |
_tInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases _gvol. 43 _gp. 232-8 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.meegid.2016.05.035 _zAvailable from publisher's website |
999 |
_c26076602 _d26076602 |